Drugs targeting C5 are investigated among others in the context of aHUS, IgA nephropathy (IgAN), LN and acute kidney injury due to COVID-19; while those targeting CFB are studied, for example, in C3G, IgAN and membranous glomerulonephritis (MGN). Here, CFB is linked to lobular neoplasia.